AA amyloidosis complicating monoclonal gammopathies, an unusual feature validating the concept of "monoclonal gammopathy of inflammatory significance"?
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
23
07
2021
received:
24
02
2021
accepted:
03
09
2021
pubmed:
8
9
2021
medline:
27
10
2021
entrez:
7
9
2021
Statut:
ppublish
Résumé
AL amyloidosis is caused by the proliferation of an immunoglobulin-secreting B cell clone. AA amyloidosis is a rare complication of chronic inflammation. However, some patients present with diseases combining monoclonal immunoglobulin production and chronic inflammation. The aim of this work was to describe cases of AA amyloidosis associated with monoclonal gammopathies. We reviewed all patients reported in French national amyloid centres presenting with AA amyloidosis and monoclonal gammopathy and performed a literature review. The quality of AA amyloidosis diagnosis and the causal relationship with monoclonal gammopathy were assessed. In total, four patients from our centres and eight from the literature fulfilled the inclusion criteria. The haematological disorders presenting with monoclonal gammopathy were as follows: Waldenström macroglobulinaemia (n = 8), Schnitzler syndrome (n = 2), multiple myeloma (n = 1) and monoclonal gammopathy of undetermined significance (n = 1). Treatment strategies varied among the cases, with the treatment of the haematological disorder in 4 and anti-inflammatory treatment in 2. Monoclonal gammopathies might be a rare and poorly known cause of AA amyloidosis. Such monoclonal gammopathies could be named "monoclonal gammopathies of inflammatory significance."
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14817Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematol Am Soc Hematol Educ Program. 2017;2017:1-12.
Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321-344.
Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361-2371.
Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562-568.
Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid. 2020;27:1-12.
Grundmann JU, Bonnekoh B, Gollnick H. Extensive haemorrhagic-bullous skin manifestation of systemic AA-amyloidosis associated with IgGlambda-myeloma. Eur J Dermatol. 2000;10:139-142.
Raghunathan V, Louis D, Wirk B. Gastrointestinal tract amyloidosis presenting with pneumatosis intestinalis. J Clin Med Res. 2017;9:654-658.
Watanabe R, Ito K, Yasuno T, et al. Persistence of renal function in a patient diagnosed with concurrent amyloid amyloidosis and immunoglobulin light chain amyloidosis. Nihon Jinzo Gakkai Shi. 2016;58:668-674.
Ishikawa H, Nakata K, Aritomi T, et al. Amyloid a protein amyloidosis in a patient with plasma cell dyscrasia. Intern Med. 2002;41:386-391.
Quinton R, Siersema PD, Michiels JJ, ten Kate FJ. Renal AA amyloidosis in a patient with Bence Jones proteinuria and ankylosing spondylitis. J Clin Pathol. 1992;45:934-936.
Riveiro-Barciela M, Martínez-Valle F, Vilardell-Tarrés M. Nephrotic syndrome and lambda light-chain monoclonal gammopathy suggestive of primary amyloidosis with positive staining for AA amyloid. J Am Geriatr Soc. 2012;60:1974-1975.
Vanderschueren S, van der Veen A. The Schnitzler syndrome: chronic urticaria in disguise: a single-centre report of 11 cases and a critical reappraisal of the literature. Clin Exp Rheumatol. 2017;35:69-73.
Conlon NP, Hayden P, Barnes L, Doran M, O’Shea F, Feighery C. Schnitzler’s syndrome; a case highlighting the complications of long-standing acquired autoinflammation. Eur J Dermatol. 2014;24:405-406.
Mittal N, Renaut P, Sharma R, Robbie M. Gastrointestinal amyloidosis associated with Schnitzler’s syndrome. Pathology. 2013;45:424-426.
Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158:182-184.
Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13:1035-1041.
Muzaffar J, Katragadda L, Haider S, Abdallah A-O, Anaissie E, Usmani SZ. Waldenström’s macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant. Acta Haematol. 2013;130:146-149.
Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, Cohen AM. Waldenström’s macroglobulinemia associated with AA amyloidosis. Int J Hematol. 2001;74:76-78.
Tatara R, Nagai T, Kobayashi H, et al. AA amyloidosis associated with macroglobulinemia. Int J Hematol. 2010;92:675-677.
Ogami Y, Takasugi M, Soejima M, et al. Waldenström’s macroglobulinemia associated with amyloidosis and crescentic glomerulonephritis. Nephron. 1989;51:95-98.
Terrier B, Jaccard A, Harousseau J-L, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine. 2008;87:99-109.
Kihara Y, Hori H, Murakami H, et al. A case of POEMS syndrome associated with reactive amyloidosis and Waldenström’s macroglobulinaemia. J Intern Med. 2002;252:255-258.
Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85:765-771.
Lust JA, Lacy MQ, Zeldenrust SR, et al. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016;91:571-574.
Elsawa SF, Novak AJ, Ziesmer SC, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011;118:5540-5549.
Terré A, Talbot A, Louvrier C, et al. Monoclonal gammopathy, arthralgias, and recurrent fever syndrome: a new autoinflammatory syndrome? J Rheumatol. 2019;15(46):1535-1539.